Osteoarthritis and cartilage
-
Osteoarthr. Cartil. · Jan 2010
Review Meta AnalysisRisk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis.
Knee osteoarthritis (OA) is common in older adults. Determination of risk factors for onset of knee OA may help in its prevention. The objective of this systematic review, and meta-analysis, was to determine the current evidence on risk factors for knee OA. ⋯ Whilst certain factors have been extensively reviewed (for example, body mass index), more longitudinal studies are needed to investigate the association of physical occupational and other patient-determined factors with future knee OA. The quality of such studies also needs to be improved. However, there are identifiable factors which can be targeted for prevention of disabling knee pain.
-
Osteoarthr. Cartil. · Nov 2008
Meta Analysis Comparative StudyResponder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis.
To determine the proportion of responders in two identical osteoarthritis (OA) trials using Outcome Measures in Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) criteria and to assess the comparability and correlation of individual component measurements. ⋯ Significantly more patients receiving etoricoxib or celecoxib than placebo were OMERACT-OARSI responders. The high correlation between individual scales composing this composite response measurement suggests some redundancies between individual components, particularly between pain and physical function.
-
Osteoarthr. Cartil. · Aug 2007
Review Meta AnalysisEfficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials.
To determine the analgesic effectiveness, the effect on physical function and the safety of opioids in patients with osteoarthritis (OA). ⋯ Opioids significantly decrease pain intensity and have small benefits on function compared with placebo in patients with OA. Adverse events, although reversible and not life threatening, often cause participants to stop taking the medication and could limit opioid usefulness. Moreover, the long-term efficacy and safety of these drugs for OA is yet to be determined due to the short mean trial duration.